A Microfluidic In Vitro Three-Dimensional Dynamic Model of the Blood-Brain Barrier to Study the Transmigration of Immune Cells

Overview

Journal Brain Sci

Publisher MDPI

Date 2022 Oct 27

PMID 36291227

Authors

Megha Meena

Robin Vandormael

Maxime De Laere

Isabel Pintelon

Zwi Berneman

Regan Watts

Nathalie Cools

Affiliations

Soon will be listed here.

Abstract

To study the biodistribution of new chemical and biological entities, an in vitro model of the blood-brain barrier (BBB) may become an essential tool during early phases of drug discovery. Here, we present a proof-of-concept of an in-house designed three-dimensional BBB biochip designed by us. This three-dimensional dynamic BBB model consists of endothelial cells and astrocytes, co-cultured on opposing sides of a polymer-coated membrane under flow mimicking blood flow. Our results demonstrate a highly effective BBB as evidenced by (i) a 30-fold increase in transendothelial electrical resistance (TEER), (ii) a significantly higher expression of tight junction proteins, and (iii) the low FITC-dextran permeability of our technical solution as compared to a static in vitro BBB model. Importantly, our three-dimensional BBB model effectively expresses P-glycoprotein (Pg-p), a hallmark characteristic for brain-derived endothelial cells. In conclusion, we provide here a complete holistic approach and insight to the whole BBB system, potentially delivering translational significance in the clinical and pharmaceutical arenas.

Citing Articles

Modular cone-and-plate device for mechanofluidic assays in Transwell inserts.

Chavarria D, Georges K, OGrady B, Hassan K, Lippmann E Front Bioeng Biotechnol. 2025; 13:1494553.

PMID: 39931136 PMC: 11807968. DOI: 10.3389/fbioe.2025.1494553.

Advances in modeling permeability and selectivity of the blood-brain barrier using microfluidics.

Sun J, Song S Microfluid Nanofluidics. 2025; 28(7.

PMID: 39781566 PMC: 11709447. DOI: 10.1007/s10404-024-02741-z.

Neural Cell Interactions with a Surgical Grade Biomaterial Using a Simulated Injury in Brain Organotypic Slices.

Wiseman J, Chari D J Funct Biomater. 2024; 15(12).

PMID: 39728162 PMC: 11678806. DOI: 10.3390/jfb15120362.

Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for development of targeted drug delivery and personalized therapy approaches.

Zimina T, Sitkov N, Gareev K, Mikhailova N, Combs S, Shevtsov M Front Med (Lausanne). 2024; 11:1452298.

PMID: 39629230 PMC: 11611596. DOI: 10.3389/fmed.2024.1452298.

Modelling the innate immune system in microphysiological systems.

Rupar M, Hanson H, Rogers S, Botlick B, Trimmer S, Hickman J Lab Chip. 2024; 24(15):3604-3625.

PMID: 38957150 PMC: 11264333. DOI: 10.1039/d3lc00812f.

References

Gajdacs M . The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules. 2019; 24(5). PMC: 6429336. DOI: 10.3390/molecules24050892. View

Meena M, Van Delen M, De Laere M, Sterkens A, Costas Romero C, Berneman Z . Transmigration across a Steady-State Blood-Brain Barrie Induces Activation of Circulating Dendritic Cells Partly Mediated by Actin Cytoskeletal Reorganization. Membranes (Basel). 2021; 11(9). PMC: 8472465. DOI: 10.3390/membranes11090700. View

Jaramillo B, Ponce A, Moreno J, Betanzos A, Huerta M, Lopez-Bayghen E . Characterization of the tight junction protein ZO-2 localized at the nucleus of epithelial cells. Exp Cell Res. 2004; 297(1):247-58. DOI: 10.1016/j.yexcr.2004.03.021. View

Workman M, Svendsen C . Recent advances in human iPSC-derived models of the blood-brain barrier. Fluids Barriers CNS. 2020; 17(1):30. PMC: 7178976. DOI: 10.1186/s12987-020-00191-7. View

de Lange E, Vd Berg D, Bellanti F, Voskuyl R, Syvanen S . P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling. Eur J Pharm Sci. 2018; 124:61-70. DOI: 10.1016/j.ejps.2018.08.022. View

Clark P, Manes T, Pober J, Kluger M . Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations. J Invest Dermatol. 2006; 127(4):762-74. DOI: 10.1038/sj.jid.5700670. View

Alavijeh M, Chishty M, Qaiser M, Palmer A . Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2006; 2(4):554-71. PMC: 1201315. DOI: 10.1602/neurorx.2.4.554. View

JONES H, Keep R, Butt A . The development of ion regulation at the blood-brain barrier. Prog Brain Res. 1992; 91:123-31. DOI: 10.1016/s0079-6123(08)62326-2. View

Malek A, Izumo S . Mechanism of endothelial cell shape change and cytoskeletal remodeling in response to fluid shear stress. J Cell Sci. 1996; 109 ( Pt 4):713-26. DOI: 10.1242/jcs.109.4.713. View

10.

B Sanchez A, Calpena A, Mallandrich M, Clares B . Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments. Pharmaceutics. 2019; 11(12). PMC: 6956211. DOI: 10.3390/pharmaceutics11120638. View

11.

Wolburg H, Lippoldt A . Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2003; 38(6):323-37. DOI: 10.1016/s1537-1891(02)00200-8. View

12.

Ballermann B, Dardik A, Eng E, Liu A . Shear stress and the endothelium. Kidney Int Suppl. 1998; 67:S100-8. DOI: 10.1046/j.1523-1755.1998.06720.x. View

13.

Bart J, Willemsen A, Groen H, van der Graaf W, Wegman T, Vaalburg W . Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage. 2003; 20(3):1775-82. DOI: 10.1016/s1053-8119(03)00405-1. View

14.

Bickel U, SCHUMACHER O, Kang Y, Voigt K . Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther. 1996; 278(1):107-13. View

15.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

16.

Abbott N . Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002; 200(6):629-38. PMC: 1570746. DOI: 10.1046/j.1469-7580.2002.00064.x. View

17.

Williams-Medina A, Deblock M, Janigro D . Models of the Blood-Brain Barrier: Tools in Translational Medicine. Front Med Technol. 2022; 2:623950. PMC: 8757867. DOI: 10.3389/fmedt.2020.623950. View

18.

Lutzky V, Carnevale R, Alvarez M, Maffia P, Zittermann S, Podhajcer O . Platelet-endothelial cell adhesion molecule-1 (CD31) recycles and induces cell growth inhibition on human tumor cell lines. J Cell Biochem. 2006; 98(5):1334-50. DOI: 10.1002/jcb.20769. View

19.

Nair M, Jayant R, Kaushik A, Sagar V . Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016; 103:202-217. PMC: 4935582. DOI: 10.1016/j.addr.2016.02.008. View

20.

Zhang S, Wan Z, Kamm R . Vascularized organoids on a chip: strategies for engineering organoids with functional vasculature. Lab Chip. 2021; 21(3):473-488. PMC: 8283929. DOI: 10.1039/d0lc01186j. View